title: Intestinal transplantation in children: a summary of clinical outcomes and prognostic factors in 108 patients from a single center.
abstract: We performed 124 intestinal transplants on 108 children (median age, 1.5 years) since 1994. Initial graft types included isolated intestine (I) (n=26), liver and intestine (LI) (n=26), multivisceral (MV) (n=50), and multivisceral without liver (MMV) (n=6). Four groups were defined by type of induction therapy: none, OKT3, or cyclophosphamide (August 1994-December 1997, n=25), early experience with daclizumab (January 1998-December 2000, n=26), recent experience with daclizumab (January 2001-April 2004, n=40), and Campath-1H (January 2001-April 2004, n=17). Actuarial patient survival at 1 year for groups 1-4 was 44%+/-10%, 54%+/-10%, 83%+/-6%, and 41%+/-12%, respectively, with group 3 having the most favorable survival (P=0.0004). Using Cox stepwise regression, the hazard rate of developing severe rejection was significantly higher in patients with transplant type I or LI (P=0.0002), with no difference between these groups (P=0.24) but a significantly higher rate for LI versus MV (P=0.005). Three factors associated with improved patient survival were recipient of MV or MMV (P=0.008), age at transplantation greater than 1 year (P=0.01), and use of daclizumab (P=0.0006). Cause-specific hazard analysis revealed a decreased rate of rejection-related mortality for recipients of MV or MMV (P=0.0007), whereas age greater than 1 year indicated a lower rate of infection-related mortality (P=0.0009). Pediatric intestinal transplantation provides an increasingly realistic chance of survival, particularly with the more recent use of daclizumab and multivisceral transplantation. A protective effect of multivisceral transplantation appears to exist with respect to the development of severe rejection.
authors.affiliation: Division of Transplantation, University of Miami, School of Medicine, Miami, Florida 33136, USA. tkato@med.miami.edu
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Kato
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Gaynor
authors.forename: Genarro
authors.initials: G
authors.lastname: Selvaggi
authors.forename: Naveen
authors.initials: N
authors.lastname: Mittal
authors.forename: John
authors.initials: J
authors.lastname: Thompson
authors.forename: Gwenn E
authors.initials: GE
authors.lastname: McLaughlin
authors.forename: Seigo
authors.initials: S
authors.lastname: Nishida
authors.forename: Jang
authors.initials: J
authors.lastname: Moon
authors.forename: David
authors.initials: D
authors.lastname: Levi
authors.forename: Juan
authors.initials: J
authors.lastname: Madariaga
authors.forename: Phillip
authors.initials: P
authors.lastname: Ruiz
authors.forename: Andreas
authors.initials: A
authors.lastname: Tzakis
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003520:Cyclophosphamide / Q000627:therapeutic use; D000077561:Daclizumab; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D007422:Intestines / Q000637:transplantation*; D016031:Liver Transplantation; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use; D016377:Organ Transplantation / Q000401:mortality; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D003520:Cyclophosphamide; D000077561:Daclizumab